Dialysis Dilemma: Which Type Offers Better Survival with Artery Disease?
"A 6-year study reveals surprising survival differences between hemodialysis and peritoneal dialysis patients with subclinical peripheral artery disease."
For individuals grappling with end-stage renal disease (ESRD), the road is fraught with challenges, especially when cardiovascular complications enter the picture. Peripheral artery disease (PAD), a condition affecting blood flow to the limbs, is a frequent and dangerous co-conspirator in ESRD, significantly raising the risk of mortality. Choosing the right treatment approach becomes paramount, and the two main options, hemodialysis (HD) and peritoneal dialysis (PD), have been a topic of intense debate among medical professionals.
Both hemodialysis and peritoneal dialysis serve as critical renal replacement therapies, but questions linger about their comparative effectiveness, particularly for high-risk groups. While some studies suggest they're equivalent, others point to conflicting outcomes, especially when considering pre-existing conditions like cardiovascular disease. This raises a crucial question: Can one dialysis modality offer a survival advantage for ESRD patients also battling PAD?
A recent study, published in the International Journal of Medical Sciences, sought to answer this very question. Researchers compared survival rates between HD and PD patients who also had subclinical PAD, defined as an ankle-brachial index (ABI) of less than 0.9. The findings revealed some unexpected differences, offering new insights into optimizing treatment strategies for this vulnerable population. This article breaks down the study's methodology, results, and what they mean for patients and healthcare providers alike.
PAD and Dialysis Risk
Peripheral artery disease (PAD) may already be present when dialysis begins, and research has examined whether its presence is associated with mortality compared with no PAD. A 2024 narrative review evaluates the epidemiology, pathophysiology, outcomes, and management of PAD in people with end-stage renal disease. A 2025 study focused on predicting two-year overall survival in dialysis patients with symptomatic lower extremity arterial disease after endovascular therapy. Another study involving 78,607 dialysis access procedures reported that increasing PAD severity was independently associated with higher 30-day mortality.
Limits of Current Practice
Management decisions for dialysis patients with artery disease generally require balancing vascular treatment, dialysis access needs, and overall prognosis. However, the available evidence does not establish a single approach that is best for every patient or directly resolve which dialysis modality offers superior survival. Outcomes may vary with disease severity, comorbid illness, access considerations, and the timing of intervention. These uncertainties support individualized clinical assessment rather than assuming that one standard method will produce the same result for all patients.
PAD and Dialysis Access Evidence
Earlier work highlighted that PAD is a systemic disease affecting the body's vasculature, not only the legs. The available reports also identified limited evidence on how PAD diagnosis and progression affect outcomes after upper-extremity arteriovenous fistula creation for dialysis access. This gap helped frame dialysis access outcomes as an important area for vascular research. The same evidence limitation was described in reports addressing upper-extremity arteriovenous fistula creation for dialysis access.
HD vs. PD: Unpacking the Survival Rates
The research team followed 91 patients with both ESRD and subclinical PAD over six years, carefully tracking their outcomes and causes of mortality. What they discovered challenges some common assumptions about dialysis treatment. The study revealed that patients undergoing peritoneal dialysis (PD) had a statistically significant higher mortality rate compared to those undergoing hemodialysis (HD).
- Higher Cardiovascular Mortality in HD: Interestingly, the study found that HD patients experienced a higher rate of cardiovascular-related deaths compared to the PD group.
- Increased Risk of Infection in PD: Conversely, PD patients had a greater percentage of deaths due to infection.
- Impact of Residual Renal Function: The study also explored the role of residual renal function (the kidney's ability to still function) in PD patients. Those with no residual renal function (anuric) appeared to have worse survival outcomes.
PAD Severity and Access Outcomes
Recent research evaluates whether PAD severity is associated with postoperative complications and loss of primary patency after dialysis access creation. The study also performed separate analyses according to access type, comparing arteriovenous fistulas with arteriovenous grafts. This design addresses whether the relationship between PAD and access outcomes may differ by the type of access used. The available source describes the research question and analysis framework but does not provide specific outcome figures in the supplied material.
Unresolved Prognostic Questions
PAD is sometimes identified at the time dialysis begins, but its influence on prognosis was described as insufficiently investigated in the cited study. That study set out to compare mortality between patients with PAD at dialysis initiation and those without PAD. The research question itself shows why broad conclusions about survival can be difficult when PAD status is not consistently evaluated at the start of dialysis. The supplied source does not report the comparison's numerical results, so a specific mortality estimate cannot be stated here.
Peritoneal Dialysis Versus Hemodialysis
Peripheral artery disease is recognized in the cited literature as a mortality risk among patients with end-stage renal disease. One study specifically compared survival between patients with subclinical PAD receiving peritoneal dialysis and those receiving hemodialysis. A separate 2026 study aimed to compare long-term outcomes in patients with peripheral arterial occlusive disease according to hemodialysis status, without prior vascular interventions. The supplied material identifies these comparative aims but does not provide enough results to conclude that peritoneal dialysis or hemodialysis consistently offers better survival.
Making Informed Decisions: What This Means for Patients and Doctors
The study's findings underscore the importance of individualized treatment plans for ESRD patients with PAD. While HD may offer a survival advantage in this specific scenario, the choice of dialysis modality should always be a collaborative decision between the patient and their nephrologist, considering the patient's overall health status, lifestyle, and preferences.
Personalized Risk Assessment
The cited research supports treating dialysis patients with PAD as a high-risk population requiring careful survival assessment. A 2025 study developed a nomogram to predict two-year overall survival in dialysis patients with symptomatic lower extremity arterial disease after endovascular therapy. Separate research evaluates whether PAD severity affects postoperative complications and primary patency after dialysis access creation, including both arteriovenous fistulas and grafts. Paclitaxel-coated devices are used to reduce restenosis after endovascular therapy, but their safety and efficacy in dialysis-dependent patients remain unclear according to the cited 2026 report.
What Research Must Clarify
Future studies need to clarify how PAD severity, dialysis modality, vascular access type, and endovascular treatment interact to influence survival. Prospective comparisons may help distinguish the effects of patient selection from the effects of peritoneal dialysis or hemodialysis themselves. Better prognostic tools could also support more individualized decisions for patients with symptomatic disease. Until stronger comparative evidence is available, claims that one dialysis type universally provides better survival should remain cautious.
A Complex Clinical Landscape
Dialysis patients with artery disease face several overlapping clinical decisions rather than a single treatment choice. PAD can affect limb health, dialysis access, procedural risk, and survival, while the available evidence remains uneven across these outcomes. Differences in disease severity and access type can make results difficult to generalize from one patient group to another. This complexity limits simple conclusions about dialysis modality based on PAD alone.
Decisions Beyond the Dataset
In real-world care, the choice of revascularization strategy may depend on whether an autologous vein is available and whether the patient is expected to live at least two years. The cited source emphasizes that life expectancy is difficult to predict in actual clinical situations. Research also examines whether PAD severity is linked to postoperative complications and loss of primary patency after dialysis access creation, including arteriovenous fistulas and grafts. These factors can make treatment planning highly individualized for patients living with both dialysis dependence and PAD.
Moreover, this research emphasizes the need for careful monitoring and management of cardiovascular risk factors in all ESRD patients, regardless of dialysis type. Vigilant attention to blood pressure, cholesterol levels, and other risk factors can help mitigate the dangers of PAD and improve overall outcomes.
While this study provides valuable insights, it also calls for further research. Larger, prospective studies are needed to confirm these findings and to investigate the underlying mechanisms driving the observed differences in survival rates. Understanding these mechanisms could pave the way for more targeted and effective interventions to improve the lives of ESRD patients with PAD. Furthermore, additional studies can reveal the importance of residual function and its correlation with PAD, especially for PD patients.